# Therapeutic Targeting Across Multiple Tumor Types: TRK Fusion Inhibition

#### **FACULTY**

### Stephen Liu, MD

Associate Professor of Medicine Division of Hematology and Oncology Georgetown University Washington, DC

#### **PROGRAM OVERVIEW**

MedGames is a comprehensive and interactive gamification-based CME activity that presents important topics in tropomyosin receptor kinase (TRK) fusion-positive tumors. The educational format of this program is unique and engaging and covers oncogenesis of TRK fusion, clinical data and mechanism of action of TRK inhibitors, and the guideline recommendations of tumor-agnostic treatments for management of TRK fusion-positive tumors. This program is hosted by Ken Jennings, guest host of a popular game show, and features Stephen Liu, MD, an expert in the treatment and management of nmCRPC.

### **TARGET AUDIENCE**

This activity is designed to educate community medical oncologists, pediatric medical oncologists, pathologists, oncology nurses and other health care providers involved in the care of patients with advanced TRK fusion-positive cancers in adults and children.

#### **LEARNING OBJECTIVES**

Upon the completion of this program, attendees should be able to:

- Review how TRK fusion mutations drive oncogenesis in solid tumors
- Discuss the anti-TRK targeted clinical trials data for both children and adults with fusion-positive cancer
- Discuss the data supporting the treatment and testing guidelines for TRK fusion-positive tumors in both children and adults

#### **ACCREDITATION STATEMENT**

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

### **CREDIT DESIGNATION STATEMENT**

Med Learning Group designates this enduring activity for a maximum of .75 AMA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

## **NURSING CREDIT INFORMATION**

Purpose: Education regarding the management of *NTRK* fusion-positive cancers leads to safe practice, quality care, and continued professional and personal development for oncology nurses. Credits: .75 ANCC Contact Hour.

**CNE Accreditation Statement**: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Awarded .75 contact hour of continuing nursing education of RNs and APNs.

### **DISCLOSURE POLICY STATEMENT**

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

### **DISCLOSURE OF CONFLICTS OF INTEREST**

**Stephen Liu, MD** reports that he serves as a consultant for Amgen, AstraZeneca, Beigene, Blueprint, Bristol Myers Squibb, Daiichi Sankyo, Elevation Oncology, G1 Therapeutics, Genentech/Roche, Guardant Health, Inivata, Janssen, Jazz Pharmaceuticals, Lilly, Merck/MSD, Pfizer, PharmaMar, Regeneron, Takeda, and Turning Point Therapeutics. He has contracted research (to institution) for Alkermes, Bayer, Blueprint, Bristol Myers Squibb, Elevation Oncology, Erasca, Genentech, Lilly, Merck, Merus, Pfizer, Rain Therapeutics, RAPT, and Turning Point Therapeutics.

#### **CME Content Review**

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

## **CNE Content Review**

The content of this activity was peer reviewed by a nurse reviewer.

The reviewer of this activity has nothing to disclose.

### **Staff Planners and Managers**

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.

Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.

Angela Davis, PhD, Medical Director for Med Learning Group, has nothing to disclose.

Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.

Ashley Whitehurst, Program Manager for Med Learning Group, has nothing to disclose.

Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

### **DISCLOSURE OF UNLABELED USE**

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

## **METHOD OF PARTICIPATION**

There are no fees for participating and receiving CME credit for this activity. To receive CME/CNE credit participants must:

- Read the CME/CNE information and faculty disclosures.
- 2. Participate in the activity.
- 3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

## DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at <a href="mailto:info@medlearninggroup.com">info@medlearninggroup.com</a>. Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

### **AMERICANS WITH DISABILITIES ACT**

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com





Co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.